Xevinapant or placebo plus chemoradiotherapy in locally advanced squamous cell carcinoma of the head and neck: TrilynX phase III study design
Authors:
Open Access
- 17 February 2022
- journal article
- research article
- Published by Taylor & Francis in Future Oncology
- Vol. 18 (14) , 1669-1678
Abstract
Xevinapant is a first-in-class antagonist of inhibitor of apoptosis proteins, which enhances cancer cell sensitivity to chemotherapy and radiotherapy. In a phase II randomized study in patients wit... Plain language summary Xevinapant is being developed as a new type of cancer treatment. Xevinapant works by enhancing the effects of chemotherapy and radiotherapy (chemoradiotherapy), which are sta...Keywords
Funding Information
- Merck
This publication has 39 references indexed in Scilit:
- Treatment choice for locally advanced head and neck cancers on the basis of risk factors: biological risk factorsAnnals of Oncology, 2012
- AT-406, an orally active antagonist of multiple inhibitor of apoptosis proteins, inhibits progression of human ovarian cancerCancer Biology & Therapy, 2012
- Targeting IAP proteins for therapeutic intervention in cancerNature Reviews Drug Discovery, 2012
- Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): A comprehensive analysis by tumour siteRadiotherapy and Oncology, 2011
- A Potent and Orally Active Antagonist (SM-406/AT-406) of Multiple Inhibitor of Apoptosis Proteins (IAPs) in Clinical Development for Cancer TreatmentJournal of Medicinal Chemistry, 2011
- IAP inhibitors enhance co-stimulation to promote tumor immunityJournal of Experimental Medicine, 2010
- Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): An update on 93 randomised trials and 17,346 patientsRadiotherapy and Oncology, 2009
- Tumor resistance to apoptosisInternational Journal of Cancer, 2008
- Multidisciplinary Management of Locally Advanced SCCHN: Optimizing Treatment OutcomesThe Oncologist, 2008
- IAP proteins: sticking it to SmacBiochemical Journal, 2004